Esperion's drug lowers blood fat in mid-stage study
Sept 3 (Reuters) - Esperion Therapeutics Inc said its drug reduced levels of bad blood fat in a mid-stage trial among patients with high levels of cholesterol, when added to a standard of care treatment.
The company said the drug lowered bad cholesterol by an additional 22 percent, compared with a placebo, after eight weeks of use with another drug atorvastatin. The placebo group showed no additional reduction in cholesterol.
The drug was well tolerated and no serious adverse events were reported, Esperion said.
- U.S.'s Kerry expresses regret to India over diplomat case |
- Mega Millions winners in Georgia, California to split $648 million |
- Washington, DC city council raises minimum wage to $11.50/hr in 2016
- China confirms near miss with U.S. ship in South China Sea
- Fed cuts bond buying in first step away from historic stimulus |